Intelligence Centre
AI Visibility is an important hygiene factor, but visibility alone does not create meaningful differentiation. Our free insights provide a glimpse of who is leading and who is lagging.
Data used for the free insights on this page
These figures reflect only part of the Theralexis intelligence database: the data used to build the free insights published on this page.
Benchmarks
Click through our interactive dashboards to see how pharma brands compete across AI models. Feel free to use or publish the data with reference to Theralexis.com.
AI Visibility & Competitive Preference
An analysis of 25 molecules, with 42 head-to-head pairs. How four AI systems name rheumatoid arthritis therapies, which they favour when asked to compare two, and how the question and the patient change the verdict.
MoleculeAI Visibility
AI Visibility & Prominence
An analysis of 22 molecules, with 5 clinical settings. Which treatments AI names for oncologists in Spain across clinical settings, question types and AI systems — and why being named is not the same as being named first.
MoleculeAI Visibility
AI Visibility & Prominence
An analysis of 62 molecules, with 7 competitive classes. Which treatments AI names in English-language questions about metastatic breast cancer, by subtype, class and AI system — and which it names first.
MoleculeAI Visibility
AI Visibility & Prominence
An analysis of 11 brands and 10 molecules, with 5 treatment options. Which advanced melanoma treatments ChatGPT, Claude, Gemini and Perplexity name — and which they name first, by question, by BRAF status and by AI system.
MoleculeAI Visibility
AI Visibility Benchmark
An analysis of 15 brands and 27 molecules, with 8 question themes. How ChatGPT, Claude, Gemini and Perplexity represent psoriasis therapies — by clinical question, by AI system, and for the next generation of treatments.
MoleculeAI Visibility
AI Visibility Benchmark
An analysis of 28 molecules. AI Visibility across five areas of the treatment conversation, in ChatGPT, Claude, Gemini and Perplexity.
MoleculeAI Visibility
AI Visibility Benchmark
An analysis of 7 brands and 7 molecules, with 2 therapy classes and 5 mechanisms. AI Visibility measured across ChatGPT, Claude, Gemini and Perplexity.
MoleculeAI Visibility
AI Visibility & Share of Voice
An analysis of 45 brands and 21 molecules. AI Visibility and Share of Voice measured across ChatGPT, Claude, Gemini and Perplexity.
MoleculeAI Visibility
No published benchmark matches this combination of filters.
Research
Our own studies of how healthcare professionals are using AI, and what that means for the companies whose therapies they are asking about.
Research
What healthcare professionals at EADV Congress 2026 told us about using generative AI for medical information.
53%reported that AI had influenced a treatment decision
Research
What healthcare professionals at ESC Congress 2026 told us about using generative AI for medical information.
70%reported that AI had influenced a treatment decision
AI systems are becoming an important layer through which pharmaceutical, therapeutic and scientific information is accessed, summarised and interpreted. Much of the public conversation still focuses on whether these systems are being adopted, rather than on the quality, emphasis and strategic implications of the answers they produce.
The Theralexis Intelligence Centre examines selected patterns in how brands, therapies, competitors, evidence and sources are represented across AI systems. The aim is to help pharmaceutical leaders recognise broader patterns and understand their potential strategic implications, while client work remains tailored, confidential and configured around a specific question.
Public analysis keeps observed evidence separate from interpretation. Publications share selected findings and their strategic implications; they do not reproduce complete datasets or the proprietary methods behind Theralexis assessments.
This area publishes independent research, original benchmarks and perspectives on how AI systems represent therapies, brands, evidence and sources across the market. It does not contain organisation-specific assessments or recommendations.
Theralexis Solutions translate that intelligence into assessments configured around a specific brand, portfolio, market or strategic question — confidential, and separate from anything published here.
Discuss how Theralexis could assess a brand, therapy, market or representation question in greater depth.